HIV Drugs Could Prevent Diabetes, Study Suggests

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent Type 2 diabetes, a new study suggests. 

Researchers found that patients taking the drugs had a 33% lower risk of developing diabetes. The scientists say that the risk reduction makes sense based on how the drugs are known to work, and noted that one of the drugs, lamivudine, improved insulin sensitivity significantly in human cell samples and in a mouse model of diabetes. (In Type 2 diabetes, the body loses the ability to use insulin, a hormone, to control blood sugar effectively.)

“The fact that the protective effect against the development of diabetes was replicated in multiple databases, in studies from multiple institutions, enhances confidence in the results,” researcher Dr. Jayakrishna Ambati of the University of Virginia School of Medicine said. “We are grateful to the UVA Strategic Investment Fund for enabling us to demonstrate the power of big data archeology to rapidly identify existing, approved drugs to repurpose for diseases that have an enormous impact, both globally and in Virginia.”

The Diabetes Pandemic

Nearly 500 million people worldwide have diabetes – primarily Type 2, or adult-onset, diabetes – and that number is expected to soar in the coming years. This carries a tremendous health burden, as diabetes is associated with many chronic medical conditions, including heart disease, atherosclerosis (hardening of the arteries), nerve damage, vision loss and impaired wound healing. 

The urgency of the situation has scientists desperately hunting for better ways to prevent and manage diabetes. To determine if drugs known as nucleoside reverse-transcriptase inhibitors, or NRTIs, might help, Ambati and colleagues from multiple institutions analyzed five databases encompassing a diverse group of 128,861 patients with HIV-1 or hepatitis B. The primary database consisted of the Veterans Health Administration, the largest integrated health system in the United States, and was reviewed from 2000 to 2017.  

The scientists found that patients taking NRTIs were more than 30% less likely to develop diabetes. Based on their analysis, the researchers predict there is a 95% chance that the drugs would reduce diabetes risk by 29% in a clinical trial. 

Dr. Jayakrishna Ambati, a UVA researcher and professor of ophthalmology, is part of a team that found that patients taking drugs used to treat HIV had a lower risk of developing diabetes. (Contributed photo)

To better understand the findings, the researchers examined the effect of lamivudine and two other drugs from the class in human cell samples. All three proved beneficial, prompting the scientists to conclude that the class as a whole is likely helpful in preventing diabetes. Notably, the research identified a connection between diabetes and dysregulation of the inflammasome, previously linked to both Alzheimer’s disease and macular degeneration.

“The large scale of these clinical data and the size of the protective effect provide evidence that inflammasome inhibition in humans is beneficial,” Ambati said. “We are hopeful that prospective clinical trials will establish that inflammasome inhibitors known as kamuvudines, which are less-toxic derivatives of NRTIs, will be effective not only in diabetes, but also in macular degeneration and Alzheimer’s disease.”

Findings Published 

The researchers have published their findings in the scientific journal Nature Communications. The research team consisted of Ambati, Joseph Magagnoli, Hannah Leung, Shao-bin Wang, Chris A. Andrews, Dongxu Fu, Akshat Pandey, Srabani Sahu, Siddharth Narendran, Shuichiro Hirahara, Shinichi Fukuda, Jian Sun, Lekha Pandya, Meenakshi Ambati, Felipe Pereira, Akhil Varshney, Tammy Cummings, James W. Hardin, Babatunde Edun, Charles L. Bennett, Kameshwari Ambati, Benjamin J. Fowler, Nagaraj Kerur, Christian Röver, Norbert Leitinger, Brian C. Werner, Joshua D. Stein, S. Scott Sutton and Bradley D. Gelfand.

The researchers were supported by the UVA Strategic Investment Fund; National Institutes of Health, grants DP1GM114862, R01EY022238, R01EY024068, R01EY028027, R01EY029799, K99EY024336, R00EY024336, R01AI48741, R21EY030651, T32HL091812, UL1RR033173, R01EY028027, R01DK096076, P01HL120840 and R01CA165609; the John Templeton Foundation, grant 6076; the DuPont Guerry III Professorship; the Beckman Initiative for Macular Research; the American Heart Association; Doris Levkoff Meddin; the South Carolina SmartState Program; and the Japan Eye Bank Association. 

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.